Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
News about CVS Health Corporation (NYSE: CVS) covers developments across its roles in retail pharmacy, pharmacy benefit management, health insurance and health care delivery. Company press releases and related disclosures highlight how CVS Health communicates financial performance, strategic priorities, governance updates and community initiatives to investors, customers and the public.
Investors following CVS stock can find news on quarterly and full-year earnings announcements, financial guidance updates and Investor Day presentations. For example, CVS Health has issued press releases discussing results for specific quarters, updating full-year financial guidance and providing outlooks for future years, including projections for revenues, operating income, adjusted operating income, GAAP diluted earnings (loss) per share and adjusted EPS. These communications often appear in conjunction with Form 8-K filings that furnish the underlying press releases.
Corporate governance and leadership changes are another recurring news theme. CVS Health has announced Board decisions such as appointing its President and Chief Executive Officer, J. David Joyner, to the additional role of Chair of the Board, and it has used both press releases and Form 8-K filings to describe these actions and related Board structures.
Operational and community-focused news items describe how CVS Health engages with public health and local organizations. Examples include offering the measles-mumps-rubella (MMR) vaccine at select CVS Pharmacy and MinuteClinic locations in South Carolina during a measles outbreak, and the CVS Health Foundation’s grants to the American Diabetes Association to expand a maternal diabetes program in New York City. Other stories highlight investments in affordable housing projects and the company’s reported economic impact across U.S. states.
Visitors to this news page can review these types of announcements to understand how CVS Health presents its strategy, financial outlook, health services, community partnerships and responses to health challenges over time.
CVS Health announced early results of its cash tender offer for multiple series of senior notes, with a maximum purchase price of $1.77 billion. The tender offer includes ten different series of notes with various interest rates and maturities ranging from 2030 to 2050. As of December 13, 2024, significant portions of various notes have been tendered, with participation rates ranging from 14.56% to 70.61%.
The company will settle the tender offer early on December 18, 2024. The total consideration will be calculated based on U.S. Treasury yields plus fixed spreads, and includes an early tender payment of $30 per $1,000 principal amount. Due to reaching the maximum tender amount, no additional notes will be purchased after the early settlement date.
CVS Health announced the results of its cash tender offer for its 4.100% Senior Notes due 2025. As of December 6, 2024, $225,979,000 in principal amount was validly tendered, with an additional $5,000 tendered under guaranteed delivery procedures. The settlement date is expected to be December 11, 2024.
The company plans to fund the purchase using proceeds from its newly issued 7.000% Series A Junior Subordinated Notes due 2055 and 6.750% Series B Junior Subordinated Notes due 2054. CVS Health expects to accept all validly tendered notes for purchase.
This tender offer is part of a larger initiative that includes a Maximum Tender Offer with a maximum purchase price of $2,000,000,000, less the amount paid for the Any and All Notes.
CVS Health has announced pricing details for its cash tender offer for all outstanding 4.100% Senior Notes due 2025. The total consideration is $998.22 per $1,000 principal amount of notes, with a reference yield of 4.434%. The tender offer expires at 5:00 p.m., New York City time, on December 6, 2024.
The settlement date is expected to be December 11, 2024. Holders will receive accrued and unpaid interest in addition to the total consideration. The offer affects $950,087,000 in outstanding notes. Holders can withdraw tendered notes until the withdrawal deadline of 5:00 p.m., December 6, 2024.
The tender offer is not conditioned on minimum participation but is subject to a financing condition and other general conditions.
CVS Health has announced key leadership appointments in its Pharmacy and Consumer Wellness division. Len Shankman has been named president of Pharmacy and Consumer Wellness (PCW), overseeing front store and retail pharmacy operations across 9,000+ CVS Pharmacy locations. Lucille Accetta has been appointed chief pharmacy officer. Both will report to Prem Shah, group president. The company recently reported positive trends, including a record-high retail pharmacy prescription share of 27.3% and significant progress in transitioning to the CVS CostVantage model, with agreements covering over half of total commercial prescriptions.
CVS Health has announced cash tender offers for certain outstanding notes, including any and all of its 4.100% Senior Notes due 2025 and several other series of notes under a Maximum Tender Offer. The total maximum purchase price across both tenders will not exceed $2 billion. The company plans to fund these purchases using proceeds from a future issuance of subordinated debt securities.
The Any and All Notes tender expires on December 6, 2024, while the Maximum Tender Offer has an Early Tender Date of December 13, 2024, and final expiration on December 31, 2024. The purpose is to retire a portion of CVS Health's outstanding indebtedness.
CVS Health has appointed Dr. Sreekanth Chaguturu as President of Health Care Delivery, while maintaining his current role as Executive Vice President and Chief Medical Officer. He replaces Mike Pykosz, who is leaving the company. The company reported significant growth in its Health Care Delivery business, with Aetna members served by Signify nearly doubling year-over-year and Oak Street's at-risk membership increasing by 32%. The number of Aetna members enrolled at Oak Street has approximately quadrupled since the acquisition. Dr. Chaguturu will focus on connecting care delivery across Oak Street Health clinics, MinuteClinic locations, and Signify Health's home services.
CVS Health has appointed four new members to its Board of Directors: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. The appointments aim to enhance financial and operational performance through new thinking and industry experience. Norwalk will join the Health Services Committee, Sansone the Audit Committee, and Shulman the Management Planning and Development Committee. The Board now consists of 16 members. CVS Health and Glenview have entered into a confidentiality agreement with customary standstill provisions.
CVS Health (NYSE: CVS) announced that Chief Financial Officer Tom Cowhey will participate in a fireside chat with investors at the Wolfe 2024 Healthcare Conference on November 19, 2024, at approximately 10:20 am ET. The event will be available via audio webcast on the Investor Relations section of the CVS Health website at investors.cvshealth.com, where it will remain accessible for one year.
CVS Health announced key leadership appointments, with Prem Shah named as Group President and Steve Nelson as President of Aetna, both reporting to CEO David Joyner. Shah, who joined CVS in 2013, will oversee operational performance and integrated value creation across CVS Caremark, CVS Pharmacy, and Health Care Delivery businesses. Nelson, former CEO of ChenMed and UnitedHealthcare, brings extensive managed care experience to lead Aetna. These appointments aim to enhance the company's integrated business model and improve financial and operational performance.
CVS Health reported Q3 2024 results with total revenues increasing 6.3% to $95.4 billion. However, GAAP diluted EPS dropped to $0.07 from $1.75, and Adjusted EPS fell to $1.09 from $2.21 year-over-year. The decline was primarily due to challenges in the Health Care Benefits segment, including a $1.1 billion premium deficiency reserve charge. The company recorded restructuring charges of approximately $1.2 billion, including store closures and workforce optimization. The Health Services and Pharmacy & Consumer Wellness segments showed strong performance, with prescription volume up 6.0%. Year-to-date cash flow from operations was $7.2 billion.